Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias

被引：104

作者：

Carta, Manolo ^{[1
,2
]}

Carlsson, Thomas ^{[1
,2
]}

Munoz, Ana ^{[1
]}

Kirik, Deniz ^{[2
]}

Bjorklund, Anders ^{[1
]}

机构：

[1] Lund Univ, Dept Expt Med Sci, Wallenberg Neurosci Ctr, Neurobiol Unit, Lund, Sweden

[2] Lund Univ, Dept Expt Med Sci, Sect Neurosci, Brain Repair & Imaging Neural Syst Unit, Lund, Sweden

来源：

SEROTONIN-DOPAMINE INTERACTION: EXPERIMENTAL EVIDENCE AND THERAPEUTIC RELEVANCE | 2008年 / 172卷

关键词：

L-DOPA; dopamine; serotonin; dyskinesia; 5-HT agonists; serotonin autoreceptors;

D O I：

10.1016/S0079-6123(08)00922-9

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

Appearance of dyskinesia is a common problem of long-term Levodopa (L-DOPA) treatment in Parkinson's disease (PD) patients and represents a major limitation for the pharmacological management of the motor symptoms in the advanced stages of disease. An increasing body of evidence points to dopamine released as a false neurotransmitter from the striatal serotonin terminals as the main pre-synaptic determinant of L-DOPA-induced dyskinesia. Here we review the animal experimental and human clinical data in support of this view, which point to the serotonin system as a promising target for anti-dyskinetic therapy in PD patients under L-DOPA medication.

引用

收藏

页码：465 / 478

页数：14

相关论文

共 87 条

[31] Description of Parkinson's disease as a clinical syndrome [J].

Fahn, S .

PARKINSON'S DISEASE: THE LIFE CYCLE OF THE DOPAMINE NEURON, 2003, 991 :1-14

[32] Loss of synaptic D1 dopamine/N-methyl-D-aspartate glutamate receptor complexes in L-DOPA-induced dyskinesia in the rat [J].

Fiorentini, C ;

Rizzetti, MC ;

Busi, C ;

Bontempi, S ;

Collo, G ;

Spano, P ;

Missale, C .

MOLECULAR PHARMACOLOGY, 2006, 69 (03) :805-812

[33] A critical interaction between NR2B and MAGUK in L-DOPA induced dyskinesia [J].

Gardoni, F ;

Picconi, B ;

Ghiglieri, V ;

Polli, F ;

Bagetta, V ;

Bernardi, G ;

Cattabeni, F ;

Di Luca, M ;

Calabresi, P .

JOURNAL OF NEUROSCIENCE, 2006, 26 (11) :2914-2922

[34] Sarizotan as a treatment for dyskinesias in Parkinson's disease:: A double-blind placebo-controlled trial [J].

Goetz, Christopher G. ;

Damier, Philippe ;

Hicking, Christine ;

Laska, Eugene ;

Mueller, Thomas ;

Olanow, C. Warren ;

Rascol, Olivier ;

Russ, Hermann .

MOVEMENT DISORDERS, 2007, 22 (02) :179-186

[35] THE ENHANCEMENT BY LITHIUM OF THE 5-HT1A MEDIATED SEROTONIN SYNDROME PRODUCED BY 8-OH-DPAT IN THE RAT - EVIDENCE FOR A POSTSYNAPTIC MECHANISM [J].

GOODWIN, GM ;

DESOUZA, RJ ;

WOOD, AJ ;

GREEN, AR .

PSYCHOPHARMACOLOGY, 1986, 90 (04) :488-493

[36] Altered D1 dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates [J].

Guigoni, Celine ;

Doudnikoff, Evelyne ;

Li, Qin ;

Bloch, Bertrand ;

Bezard, Erwan .

NEUROBIOLOGY OF DISEASE, 2007, 26 (02) :452-463

[37] Role of the medial prefrontal cortex in 5-HT1A receptor-induced inhibition of 5-HT neuronal activity in the rat [J].

Hajós, M ;

Hajós-Korcsok, E ;

Sharp, T .

BRITISH JOURNAL OF PHARMACOLOGY, 1999, 126 (08) :1741-1750

[38] Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease [J].

Hallett, PJ ;

Dunah, AW ;

Ravenscroft, P ;

Zhou, S ;

Bezard, E ;

Crossman, AR ;

Brotchie, JM ;

Standaert, DG .

NEUROPHARMACOLOGY, 2005, 48 (04) :503-516

[39]

HOLLISTER AS, 1979, J PHARMACOL EXP THER, V208, P37

[40] Molecular, pharmacological and functional diversity of 5-HT receptors [J].

Hoyer, D ;

Hannon, JP ;

Martin, GR .

PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR, 2002, 71 (04) :533-554

← 1 2 3 4 5 6 7 8 9 →